Literature DB >> 28433475

Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population.

Jung Hwan Lee1, Jin-Hong Shin2, Hyung Jun Park3, Sook Za Kim4, Young Mi Jeon4, Hye Kyoung Kim2, Dae-Seong Kim2, Young-Chul Choi5.   

Abstract

We performed targeted population screening of late onset Pompe disease (LOPD) in unspecified myopathy patients, because early diagnosis is difficult due to its heterogeneous clinical features. We prospectively enrolled 90 unrelated myopathic patients who had one or more signs out of five LOPD-like clinical findings (proximal weakness, axial weakness, lingual weakness, respiratory difficulty, idiopathic hyperCKemia). Acid alpha glucosidase activity was evaluated with dried blood spot and mixed leukocyte simultaneously. For a final diagnosis of LOPD, 16 patients with decreased enzyme activity were genotyped by GAA molecular analysis. We found two patients with LOPD (2.2%), and the remaining 14 patients had at least one G576S or E689K mutation, known as the pseudodeficiency allele. Acid alpha glucosidase activity of LOPD patients was significantly lower than that of patients with at least one pseudodeficiency allele (p = 0.017). This study is the first LOPD screening study for targeted Korean population, and more generally, an Asian population. Our findings suggest that for diagnosis of LOPD in Asian population, modified cutoff value of acid alpha glucosidase activity with dry blood spot considering that of patients having heterozygote pathogenic variants or pseudodeficiency alleles may reduce time and cost requirements and increase the comfort of patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Late onset Pompe disease; Pseudodeficiency; Screening study; Unspecified myopathies

Mesh:

Substances:

Year:  2017        PMID: 28433475     DOI: 10.1016/j.nmd.2017.03.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

Review 1.  A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting.

Authors:  Ali Al Shehri; Abdullah Al-Asmi; Abdullah Mohammed Al Salti; Abubaker Almadani; Ali Hassan; Ahmed K Bamaga; Edward J Cupler; Jasem Al-Hashel; Majed M Alabdali; Mohammed H Alanazy; Suzan Noori
Journal:  J Neuromuscul Dis       Date:  2022

2.  Duchenne Muscular Dystrophy With Low Acidic α-Glucosidase Activity: Two Case Reports and Literature Review.

Authors:  Xiufang He; Xuandi Li; Yuese Lin; Hongjun Ba; Huimin Peng; Lili Zhang; Ling Zhu; Youzhen Qin; Shujuan Li
Journal:  Front Pediatr       Date:  2022-06-01       Impact factor: 3.569

3.  The First Year Experience of Newborn Screening for Pompe Disease in California.

Authors:  Hao Tang; Lisa Feuchtbaum; Stanley Sciortino; Jamie Matteson; Deepika Mathur; Tracey Bishop; Richard S Olney
Journal:  Int J Neonatal Screen       Date:  2020-02-07

4.  High-risk screening of late-onset Pompe disease: A different early portrait in China.

Authors:  Kexin Jiao; Jihong Dong; Sushan Luo; Liqiang Yu; Qing Ke; Zhiqiang Wang; Xinghua Luan; Xiaojie Zhang; Junhong Guo; Yan Chen; Xihua Li; Song Tan; Fangyuan Qian; Jianming Jiang; Xuen Yu; Dongyue Yue; Changxia Liu; Lijun Luo; Jianping Li; Yanzhou Qu; Lan Chen; Jianglong Tu; Chong Sun; Chong Yan; Jie Song; Jianying Xi; Jie Lin; Jiahong Lu; Chongbo Zhao; Wenhua Zhu; Qi Fang
Journal:  Front Neurol       Date:  2022-09-27       Impact factor: 4.086

5.  Enzyme activities of α-glucosidase in Japanese neonates with pseudodeficiency alleles.

Authors:  Ryuichi Mashima; Torayuki Okuyama
Journal:  Mol Genet Metab Rep       Date:  2017-07-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.